Response to therapy
| . | . | Arm A Day 42 (56 evaluable patients) . | Arm B Day 46 (49 evaluable patients) . | P value . |
|---|---|---|---|---|
| Initial response | CR + PR + MR | 44 (78.57%) | 46 (93.88%) | .0284 |
| NR | 12 (21.43%) | 3 (6.12%) | ||
| Arm A Day 180∗ (43 evaluable patients) | Arm B Day 180† (39 evaluable patients) | |||
| Final response | CR + PR + MR | 26 (60.47%) | 23 (58.97%) | .8907 |
| Loss of response + NR | 17 (39.53%) | 16 (41.03%) | ||
| Arm A 12 mo∗ (31 evaluable patients) | Arm B 12 mo† (36 evaluable patients) | |||
| Persistent response | CR + PR + MR | 25 (80.65%) | 20 (55.56%) | .0292 |
| NR | 6 (19.35%) | 16 (44.40%) |
| . | . | Arm A Day 42 (56 evaluable patients) . | Arm B Day 46 (49 evaluable patients) . | P value . |
|---|---|---|---|---|
| Initial response | CR + PR + MR | 44 (78.57%) | 46 (93.88%) | .0284 |
| NR | 12 (21.43%) | 3 (6.12%) | ||
| Arm A Day 180∗ (43 evaluable patients) | Arm B Day 180† (39 evaluable patients) | |||
| Final response | CR + PR + MR | 26 (60.47%) | 23 (58.97%) | .8907 |
| Loss of response + NR | 17 (39.53%) | 16 (41.03%) | ||
| Arm A 12 mo∗ (31 evaluable patients) | Arm B 12 mo† (36 evaluable patients) | |||
| Persistent response | CR + PR + MR | 25 (80.65%) | 20 (55.56%) | .0292 |
| NR | 6 (19.35%) | 16 (44.40%) |